Prevail Therapeutics
Latest round
- Series B
Last raised
- Mar 2019
Total raised
- $107M
Investors
- 12
About Prevail Therapeutics
Prevail Therapeutics, Inc.Prevail Therapeutics, Inc. is dedicated to developing gene therapies that address the causes of neurodegenerative diseases. Founded in 2017, the company is headquartered in New York, US. The CEO is Franz Hefti.04 bn upon regulatory approval of its products.Prevail Therapeutics specializes in innovative gene therapies targeting neurodegenerative diseases and rare conditions, particularly Gaucher disease and Parkinson's disease associated with GBA1 genetic variants. Their therapies enhance or introduce specific enzymes to mitigate health issues related to these conditions, aiming to resolve fat accumulation in lysosomes which can lead to organ damage.The revenue model of Prevail Therapeutics is based on partnerships with healthcare institutions and collaborations with clinical trial participants for their gene therapies. The company is focused on expanding its reach in North America and Europe. The acquisition by Eli Lilly will provide further resources for developing its therapies, which are expected to evolve into marketable products, creating significant revenue opportunities.
Who invested in Prevail Therapeutics
12 investors across 3 rounds
See all investors in Prevail Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Prevail Therapeutics
Who invested in Prevail Therapeutics?
Prevail Therapeutics has 12 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Prevail Therapeutics raised?
Prevail Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Prevail Therapeutics last raise money?
Prevail Therapeutics's most recent round on record is a Series B, in Mar 2019.
What does Prevail Therapeutics do?
Prevail Therapeutics is a biotechnology company.
Where is Prevail Therapeutics headquartered?
Prevail Therapeutics is headquartered in New York, US.
Which VCs invest in companies like Prevail Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Prevail Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Prevail Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.